PFIZER INC — Regulatory Filings 2007

May 23, 2007

8-K 1 pf8k0518.htm PFIZER INC. 8-K Pfizer Inc. 8K -May 18, 2007

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): May 18, 2007

PFIZER INC. (Exact name of registrant as specified in its charter)

Delaware	1-3619	13-5315170
(State or other Jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)
235 East 42nd Street New York, New York (Address of principal executive offices)		10017 (Zip Code)

Registrant's telephone number, including area code:

(212) 573-2323 Not Applicable (Former Name or Former Address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

[ ] Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

| Item 5.02 |
| --- |
| On May 18, 2007, the Board of Directors authorized the Company to enter
into agreements whereby Dr. John L. LaMattina, Senior Vice President;
President - Pfizer Research and Development, will retire, and Mr. Alan
G. Levin, Senior Vice President; Chief Financial Officer, will resign,
from the Company when their successors are appointed but no later than
December 31, 2007. Dr. LaMattina has served the Company for over 30 years
in various capacities, and Mr. Levin has served the Company for over 20
years in various capacities. It is expected that Dr. LaMattina and Mr. Levin will receive cash severance
payments of $3.3 million and $2.0 million, respectively, as well as the
other estimated payments and benefits set forth in the table at the bottom
of page 73 of the Company’s 2007 Definitive Proxy Statement filed
on March 15, 2007. These payments and benefits are in addition to the
payments and benefits that Dr. LaMattina and Mr. Levin will receive under
the other employee benefit plans and programs of the Company applicable
to such employees as described in the Proxy Statement. In addition, it
is expected that Dr. LaMattina and Mr. Levin will agree to certain non-competition
and cooperation covenants. Once the agreements are final, the Company
will file them with the Securities and Exchange Commission. |

SIGNATURE

Under the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the authorized undersigned.

By: /s/ Margaret M. Foran Margaret M. Foran
Title: Senior Vice President-Corporate Governance, Associate General Counsel and Corporate Secretary
Dated: May 23, 2007